RENAL homograft recipients have been reported to have a high incidence of livu disease in the post-transplantation period. 2f • 29. 31. 56. 65, 70 It was assumed that the immunosuppressive agents were responsible, either by their hepatotoxicity or because the consequent weakening of the host immune system permitted the frequent development of virus hepatitis. An accurate distinction between these two general possibilities was not feasible until recently. Then, with the description of tests which permitted identification of the hepatitis associated or Australia (Au) antigen, 7 , 9, 58 it became possible to deciSively study at least one variety of virus hepatitis in transplant recipients.
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incidence of serologic evidence of Au antigenemia, (2) Comparison of immunodiffusion, immuno-osmoelectrophoresis, electrO-immunodiffusion, and complement fixation tests for the detection of hepatitis in immunosuppressed patients, ( 3 ) Thn clinical course followed by immunosuppressed patients infected with the serum hepatitis virus, (4) Evaluation of the anticomplementary activity (ACA) recently described by Shulman and Barker 64 and Purcell et al. 60 as an indicator of complexes of Au antigen and antibody, and, (5) Description of the serologic changes and clinical course of a patient dying with chronic aggreSSive hepatitis, Au positive, who was treated with liver replacement.
Methods
Specimens were taken from 225 normal volunteers, from 83 recipients of renal homografts, from 10 liver recipients, and from one cardiac recipient. Immunosuppression for the transplant patients was with azathioprine and prednisone 65 to which horse antilymphocyte globulin (ALC) was added in about half the cases. 70 All the blood samples were allowed to clot for about one hour at room temperature. The sera were then separated by cold centrifugation and stored at -20 or -70° C. The analyses were subsequently performed independently in two laboratories. In one (hereafter called Laboratory 1) the screening was done with micro-Ouchterlony agarose gel immunodiffusion (AG), 46 or electroimmunodiffusion (EID ) 46 technics, reacting the patient's serum against standard sera known to contain Au antigen or antiAu antibody. The standard serum containing Au antigen was obtained from a patient treated with renal homotransplantation in February, 1968, who did not have obvious liver disease in spite of chronic Au antigenemia. The standard serum containing anti-Au antibody was taken from another renal recipient of approximately the same era who had developed chronic liver disease without perSistent Au antigenemia.
In Laboratory 2, fewer recipients were studied, but analysis of the sera was more exhaustive. The Au antigen was detected with the micro-Ouchterlony (AG), 53 immunoelectro-osmophoresis (IEOP), 16, 59 and complement fixation (CF) 63, 64'" tests. In all three systems quantitation was obtained by serially diluting the patient's sera with gelatin-veronal buffer (GVB++); the amount of Au antigen was expressed as the reciprocal of the greatest dilution in which a positive reaction was elicited by that test. The standard sera containing Au antigen were obtained from seven patients whose antigen appeared identical by the Ouch terlony method. One of these serum donors was a renal transplant recipient, another had chronic lymphatic leukemia, two were hemophiliacs and the other three did not have an associated disease; four of the seven patients had received multiple blood transfusions at some previous time. The serum containing anti-Au antibody was donated by the same patient described in the preceding paragraph. However, the IgG was removed from the crude serum by ammonium sulphate fractionation, followed by "One drop of guinea pig complement was used having a concentration of 1.5 CH 50 units/m!' In all sera checked for Au antigen, antiAu antibody also was looked for with AG, lEOP, and CF by reversing the positions of the patient and standard sera and using the Au-containing serum from the renal transplant recipient described earlier as the reference antigen.
The anti-complement activity (ACA) in the sera was quantitated by a hemolysis method. 43 To serial 2-fold dilutions of the patient sera was added an equal volume ( one drop) of 1.5 CH50 units/ml of normal human complement. After incubation for 60 minutes at 37° c., one drop of sensitized sheep erythrocyte suspension containing 1 X 10 8 celIs/mI. was added. Hemolysis was graded after an additional 60 minutes incubation and centrifugation at 1,000 rpm for 5 minutes.
An effort was made to distinguish ACA from the other well known heat-stable human complement inhibitor, C3 inactivator.74 C3 inactivator was looked for with the immune adherence test using the EA 4, 3 cell system. 74 In addition, rheumatoid factor ( RA) possesses anticomplementary activity. 30, 34 RA was detected with the latex fixation test."
In addition, the sera of four renal patients who were known to possess both ACA and C3 inactivator were submitted to DEAEcellulose"" column chromatography57 after special cellulose washing. 75 In addition, further purification of ACA elutions from the DEAE column was obtained by gel filtration with Sephadex G-200 and the refined product was re-examined serologically for ACA activity. The decomplemented (heated at 56° C. for 30 minutes) sera from four other paticnts who possessed high titer ACA were examined by electronmicroscopy. To two of the sera of renal recipients which had An antigen detectable by all the methods used, purified anti-Au IgG was added; the resulting precipitate was examined ultrastructurally. In addition, the ACA in the sera of two liver recipients was examined ultrastructurally after being purified by ammoniulll sulphate precipitation, DEAE chromatography, Sephadex G-200 gel filtration, pol)'"inyl chloride (Pevikon) block electrophoresis'" and recycling through Sephadex G-200. One of these hepatic patients had an ACA titer ranging as high as 1/1,024 but no serologic evidence of Au antigcnemia. The other had an ACA titer of 1:48; An antigen became detectable by CF only (Table 6) .
Results
Incidence of Au Antigen or Anti-Au Antibody In Laboratory 1 the sera from 83 renal, five hepatic, and one cardiac transplant re-""Lot ]\'0. 2·107, Brown Company, Berlin, New Hampshire.
"Pevikoll C870, Fosfatbolaect, Stockholm (5), Sweden.
cipients were studied with electroimmunodiffusion (EID) and/or with AG (Table 1) The foregoing statistics were collected by studying single serum samples obtained from the individual patients from one month to 8 years after transplantation, at re-hospitalization or at routine clinic visits. It was conceivable in some cases in which the results were negative that evidence of serum hepatitis had been present with these tests earlier, but with the resolution of the positive serologic findings. To evaluate this possibility, serial stored sera were examined both in Laboratories 1 and 2 from 3.5 of the 72 patients pronounced to be Au negative on the basis of their single samples, including the two recipients who had anti-Au antibody. In these 35 recipients (of 33 kidneys, one liver, and one heart), three to 31 serial samples were examined over collection intervals that ranged from 2 to 35 months, with an average of 14.4 ± 9.1 (S.D.) months. None of the 35 patients had the Au antigen in any of their specimens as detected with the AG, EID, and lEap examinations. Thus the single sample analysis with the precipitating technics appeared to provide adequate gross screening for posttransplantation epidemiologiC studies since no patient who exhibited the Au antigenemia with those tests ever had disappearance of the positive serologic findings. However, it will be pointed out in the next section that the incidence derived with the precipitating tests was an under estimation since several additional cases were detected by the more sensitive method of complement fixation.
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Comparative Sensitivity of Detection Methods
In the 15 recipients in the preceding section who were known to be Au positive and in one heart, one liver, and 33 renal recipients who were thought to be Au negative, serial serum samples collected over periods of one to 54 months were studied by all four of the methods shown in Table  2 . An average of 13.4 ± 11.1 (S.D.) specimens were examined from each patient. The 15 recipients who were found to have the Au antigen with the precipitating tests (AG, EID, and IEOP) were also positive with complement fixation (CF) as defined by a titer of 1:4 or higher. In addition, 8 patients of the 35 who were negative for Au antigen by the precipitating tests had Significant increases in CF at some time indicating that Au antigen had been present even though this had been missed by AG, EID, or IEOP.
In addition to proViding a higher yield, the CF was invariably the most sensitive way to follow individual patients. It became positive earlier and evolved more dramatically than any other test (Fig. 1) .
The 225 people who were thought to be 
Clinical Manifestations of Au Antigenemia
Forty-five of the non-hepatic transplant recipients (44 renal and one cardiac) who were studied serologically at frequent postoperative intervals also had concomitant liver function tests. Consequently, it was possible in these 45 cases to correlate abnormalities in hepatic function with the presence or absence of Au antigenemia.
Au Positive by All Tests. Three of the 12 kidney recipients who were repeatedly studied ( Fig. 2) had definite Au antigenemia prior to transplantation detected by the precipitating methods (AG and lEOP) as well as by CF. Two other patients were positive preoperatively with CF only; 16 and 50 months postoperatively the AG and IEOP in these two patients became positive. The details of one of the latter cases is shown in Figure 1 . In this patient, the CF test was elevated in variable titers on every occasion for more than 4 years before the diagnosis of Au antigenemia could be confirmed by AG and IEOP. The seven When an arrow is at the extreme left of an individual patient's schematic summary, the first studies were obtained sometime after the transplantation. Otherwise, the symbols to the left of the arrows represent preoperative determinations. In Cases LD 40 and LD 50, the first examinations were more than 5 years after a first transplantation, but before a second transplantation. LD 108 was studied both before and after each of his 2 transplantations which were almost 4 years apart; details of this case are also summarized in Figure 1 .
patients who had no evidence of the Au antigen before transplantation or at the time of the first examination postoperatively developed positive serologic tests from one to 35 (average 12~) months later (Fig. 2) .
Once the full battery of analyses showed the Au antigen, these findings did not permanently disappear in any instance in the subsequent followup intervals of 4 to 30 (average 13.7) months (Fig. 2) . The liver function tests of the 12 patients obtained at the same time as the various serologic examinations are summarized in Figure 2 . There was only one isolated example (Case LD 40) of serious acute hepatic malfunctions, defined as two SCOT tests exceeding 250 I. U . ( normal < 50) or bilirubin of greater than 2 mg./100 m!. Minor function abnormalities were observed at some time in six other cases, almost invariably consisting of relatively trivial inereases in SCOT (50 to 250 I. U. ). The latter transaminase abnormalities are still present in five of the 12 recipients. On the other hand, five of the patients who have had serologic evidence of hepatitis for one to more than 4 years had no evidence whatsoever of hepatic dysfunction at any time.
Au Positive by C.F. Only. One patient had an elevated CF titer before operation and another one was positive when first tested 3% years post-transplantation. The other five recipients developed positive CF examinations from 1 to 13 months (average 4.2) after operation. In contrast to the precipitating tests, a positive CF result did not neccssarily imply chronicity of Au antigenemia since reversion to normal occurred in four of the seven patients (Fig. 2) .
Abnormal liver function tests of a minor nature were seen transiently in two of the seven patients (Fig. 2) . A third recipient (LD 224) became deeply jaundiced at the same time as there was evidence of hepatic necrosis and very low grade increases in the CF ti tel'S (Fig. 3) . Except for this case, there was no correlation between abnormal CF tests and hepatic dysfunction.
Au Negative by All Tests. Of the 24 patients who never had Au antigen despite frequent testing (Fig. 4) , 14 (58.3%) had
The course of a patient (LD 224) who developed evidence of severe hepatitis after transplantation. At the same time, he had low grade increases in complement fixation titers of Au antigen as well as slightly anticomplementary activity in the serum. Note the transient secondary complement fixation titer rise more than a year later. in Figure 2 whose sera had evidence of the Au antigen but who had hepatic dysfunction at a rate of only 10 in 19 (52.6%). The liver disease in the Au negative patients was usually trivial. However, there were five patients who had serious hepatic malfunction as defined earlier in terms of SCOT and bilirubin rises. Liver disease either caused or contributed importantly to the deaths of three of these five recipients (Fig. 4, 5) .
In one of the five patients with serious liver disease, azathioprine toxicity was so strongly considered that this drug was stopped and replaced with cyclophosphamide (Fig. 6) . A marked improvement in hepatic function was noted in the ensuing 7 weeks. These observations were not thought either to weaken or strengthen the hypothesis of azathioprine hepatotoxicity in this patient.
Anti-Au Antibody. In all the patients who had Au antigen by any test, antiAu antibody was looked for with AG, lEOP, and CF, but it was never detected. In addition, all the patients with negative Au tests were examined. Two of these latter reci· pients had unequivocal evidence of anti-Au antibody (Table 3 ) which devcloped one week and one year respectively after transplantation, without ever having detectable FIG. 5. The course of a recipient (CD 17) of 4 snccessive renal homografts who despite COIlsistently negative serology for An antigen showed significant aberrations of liver function tests over a 3-year period. Following the fourth transplantation, she became deeply jaundiced and died 3 weeks later. in August, 1970 was read as chronic aggressive hepatitis with early cirrhosis.
In both cases, anti-complementary activity (ACA) has been present in low titers during most of the period of study. The interpretation of this finding will be considercd later on.
Anticomplementary Activity
Renal and Cardiac Recipients. One cardiac and 48 renal recipients who had repeatcd examinations for Au antigen also had ACA dctermination at these times. In each of the patients who was Au positive by all the detection methods, ACA was increased to or above a titer of 1: 16 (Table  4 ). The same was true for six of the seven patients who had the Au antigen detectable onlv bv CF. In contrast, onlv one of 28 patie~ts ill whom tbcre was no 'evidence of the Au antigen had an ACA titer as high as 1: 16 (Table 1) .
In the patients with Au antigen, the significant ACA titers usually developed at or about the same time as one or more of the Au test became positive, as exemplified in Figure 1 . However, this temporal association was sometimes not precise, with the ACA rising either before or after the other serologic changes. While there was a good general correlation between ACA and Au antigenemia, there was no clear association with the rheumatoid factor as detected by the Latex fixation test (Table 4) .
Hepatic Recipients. Of the hepatic recipients, there were eight whose ACA was determined serially before and after operation. All eight had significant increases of ACA titer. The elevations occurred both in patients with and in those without Au antigenemia. In fact, the highest ACA titer ( 1: 1,024) was in a child who never had any other serologic evidence of the Au antigen (Patient 5, Table 5 ). Similarly, the rheumatoid factor could not be correlated with Au antigenemia.
Normal People. There were 225 normal controls of whom none had any serologiC evidence of Au antigen (see earlier). Of this group, 208 had no ACA and the other 17 had titers of 1: 2 to 1: 8, too low to be considered significant.
The Nature of ACA. The evidence in the preceding sections (Tables 4 and 5) showed that ACA was not rheumatoid factor. In addition, the titers of C3 inactivator were determined in seven of the eight liver recipients shown in Table 5 and in 30 renal recipients (15 Au positive, 15 Au negative). These fluctuated remittently, but not in relationship to ACA. A difference between ACA and C3 inactivator was proveu by the DEAE cellulose chromatography and Sephadex G-200 gel filtration which pcrmitted separation of the two substances. With both chromatographic technics, the ACA and C3 in activator werc at widely separated peaks (Figure 7) .
The electron micrographic studies with the precipitates or purified ACA from the sera of four recipients (two renal and two hepatic) who possessed high ACA titers are summarized in Table 6 . An example of what was construed as a complex of virus and antibody is shown in Figure 8 . The only . ,. specimen that did not contain easily identifiable virus-like particles came from the purified ACA of the liver recipient who was serologically Au negative.
Liver Replacement for Chronic Aggressive Hepatitis, Au Positive
A 27-year-old woman with end-stage hepatic disease and remittent encephalopathy was treated on August 9, 1970 by total removal of a 688 Gm. cirrhotic liver and replacement with a cadaveric homograft. Between 1959 and 1964 she had been an intravenous drug user and was admitted to a Los Angeles Hospital in 1964 with a bout of acute hepatitis from which she was thought to have promptly recovered. However, in July, 1969, she was seen by Dr. Allen Rediker of the University of Southern California, Los Angeles, who diagnosed chronic aggressive hepatitis after liver biopsy. Moreover, from then until the time of transplantation almost a year later, six blood samples were Au positive by the AG test performed in California. Using stored sera, these findings were the same in the Colorado Laboratories 1 and 2. In addition, there was confirmatory evidence of persistent Au antigenemia by the IEOP, EID, and CF examinations (Fig. 9) immediately before transplantation. The ACA was also elevated (Fig. 9) .
At the time of operation, she had 9 liters of ascites, bilateral pleural effusions and jaundice. Liver function tests were typical of terminal hepatic disease including hypoalbuminemia «2.0 Gm./lOO ml.) and a depressed prothrombin time «200/0). She also had striking hypergammaglobulinemia (4 Gm./100 ml. or more).
In spitc of her poor condition prior to the transplantation, the early postoperative convalescence was uncomplicated. Immunosuppressive treatment included the use of azathioprine, prednisone, and horse ALG (Fig. 9) . Hepatic function was excellent from the beginning. The high serum concentration of gamma globulin promptly fell (Fig. 9) .
Within 30 minutes after host hepatectomy, all serologic evidence of persistent hepatitis had disappeared by the AG, EID, IEOP, CF, and ACA tests. Almost 6 weeks later, the CF, EID, and IEOP returned to positive, followed almost a month later by the same change in the AG.
One week after all the hepatitis detection tests had become positive and 80 days after the transplantation, the patient was readmitted with increases in the transaminases, Ann. Surg .. Vol. 174· No.4 Figure 8 . ' *** These virus-like particles were often surrounded by halos that were interpreted to be antibody (Fig. 8) as described by Almeida et al.1 jaundice, alkaline phosphatemia, and depression of the prothrombin time to 5070. For several days she had marked loss of appetite. The diagnosis of recurrent hepatitis was made, rather than that of delayed homograft rejection. Consequently, immunosuppression was not increased. The biochemical abnormalities of the presumed hepatitis developed and largely receded over a period of 8 weeks (Fig. 9) . However, the evidence of Australia antigenemia has persisted to the present time 8 months post-transplantation.
Discussion
It has not yet been established that the Australia antigen is the actual serum hepatitis virus. 5 , 14, 47 The most fundamental reason for withholding judgment on this question is that DNA or RNA has not been proved to be present in the Au antigen"; one or the other of these nucleic acids must be present if it is a virus. Nevertheless, the evidence suggests either that the Au antigen is the serum hepatitis virus or something very closely associated with it. The work of Krugman and Giles 36 and of Barker et al. 4 has shown that the Au antigen is infectious. Moreover, Au positive serum usually contains particles that look like viruses of the Picorna class,"' 51 approximately 200 A in diameter.l, 2, 4, 5, 20, 2R, 35, 47, 51, 58 Conceding for the moment that the Au antigen is the serum hepatitis virus, it is hardly surprising to find an increased incidence of this agent in the transplant population. In Blumberg's initial studies and in a number of subsequent ones, the Au antigen was found with increased frequency in patients with a variety of natural immunologic deficiency states including Down's syndrome, D, 13, 71, 72 leukemia,7, 9, 12 leprosy 10, 11 and uremia. 24, 37, 39, 40, 77 In our patients, an analogous host background of partial immunologic invalidism was provided by iatrogenic immunosuppression. Although reports of documented serum hepatitis under this latter circumstance have been few in number/G, 37, 41, 51, 62, 6G, 70 this is undoubtedly because technics for Au antigen detection have been widely employed only in the last year or so. It can be expected that serum hepatitis will be found in every large transplantation program providing the appropriate survey is conducted.
The incidence is only the beginning of the total problem in assessing the significance of serum hepatitis under conditions of chronic immunosuppression. Of greater import is the fact that a patient once infected under these circumstances cannot recover in the traditional sense and rid himself of the microorganism, at least as its presence is measured by the precipitating methods (AG, EID, and IEOP). example, both parents of the renal recipient whose serum serves as our Au antigen standard have developed serum hepatitis. In the last 9 years, more than a dozen of the professional team working in our transplantation unit have developed hepatitis and one, a research technician, has died. Au tests were performed only on the last three afflicted staff p ersonnel, and these were positive, including the fatal case. By personal communication, 40, 78 it is known that deaths of staff members from serum hepatitis have been observed at other transplantation and dialysis centers. The implications of serum hepatitis in the chronically·immullosuppressed recipient who has continuous viremia from which he cannot hope to recover are by no means so well known in terms of liver function over a period of years. It has been suggested hy some authorities that the virulence of hepatitis under conditions of immunosuppression is considerably less than in a normal person, 37. 62 presumably by the coincidental prevention of autoimmune sequellae of hepatocellular injury. Such opinions have been used to rationalize the wisdom of immunosuppressive treatment of patients with chronic aggressive hcpatitis. Stated differently, the proposition would predict that serum hepatitis would be less dangerous to the immunosuppressed transplant patient than to his nurses or physicians.
The foregoing hypothesis cannot be refutcd by the observations in the present investigation since there was no mortality from proven serum hepatitis amongst the studied transplantation patients whereas a non-immunosuppressed technician died during the same interval. Nevertheless, the notion that immunosuppressive agents arc liver-protective can hardly be strongly supported by a group of organ recipients of whom more than half had hepatic injury from whatever cause. The most that can be said is that serum hepatitis was not the major cause of the high incidence of hepatic damage in this patient population since the biochemical indices of injury were essentially the same with or without Au antigenemia. Because of this latter fact, exclusion of candidates for renal transplantation because of an Au positive test cannot be justiRed on the basis that the recipient would be thereby placed at an exorbitant risk.
The same conclusion applied to the patient in the present report who was dying of hepatic failure secondary to chronic aggressive hepatitis, Au positive. In this case, removal of the diseased organ was followed within a few minutes by the com-plete disappearance of all serologic evidence of the Au antigen from the peripheral blood, indicating that the primary source feeding the antigenemia had been the liver. That it was not the sole repository of the virus was suggested by the subsequent recurrence of the hepatitis at about the same time as would have been expected with an initial exposure to virus at the time of transplantation.
For infectious diseases, the incubation period is often thought of in terms of the host immunologic apparatus. A somewhat different view is necessary in our patient whose liver was replaced. In this case, the latent pcriod seemed intrinsic to the target organ, the liver. When the liver finally exhibited injury, the extrahepatic manifestations of serum hepatitis also became evident, including such complaints as excruciatingly painful joints. Recovery then followed in much the same way as after her first attack of acute serum hepatitis 6 years previously.
The long-term prognosis of this hepatic "ecipient remains guarded. However, there are two reasons to hope that her new organ will not suffer the same fate as her native liver. First, as discussed earlier, immunosuppression may help prevent the ravages of progressive hepatic disease, at least as these are dependent upon an autoimmune component. Second, the homograft may be less susceptible to chronic aggressive hepatitis if the recently propounded theories of genetic predisposition to serum hepatitis 8,"" have validity. Hepatic homografts have been proved to retain donor genetic specificity for years and probably pem1anently after transplantation. 3 , 33, 38, 45, 68, 70 Consequently, the transplantation of the liver from a donor who possessed genetically determined resistance to hepatocellular injury could be a major advantage. Third, the patient has had no sign of the hypergammaglobulinemia that was such a prominent feature before transplantation.
Although potential renal and hepatic recipients cannot logically be denied transplantation on grounds that a positive Australia antigen tests would subject them to a prohibitive risk, a decision against the undertaking could be justified on the basis that the creation of a dangerous endemic hepatitis pool within the hospital is unwarranted. After much discussion within our group, we have decided that chronic Au antigenemia should not a priori exclude patients for transplantation, providing the appropriate infectious precautions are carried out including training the patient to be impeccable about personal hygiene. It seems to us that the major problem in the past has been the unknOWing entry of hepatitis carriers into the program. The single most important identifiable source of hepatitis in our transplantation patients has been pretransplantation renal hemodialysis, accounting for almost half our cases. It may be assumed that at least some of the other half were infected by members of the first group in the course of sharing the ward facilities.
Now that Au tests are available for screening, this kind of hazard can be minimized since at least it will be known in advance which patients constitute a threat and require speCial isolation care. If hepatitis is to be kept to a minimum, othcr screening procedures will be essential, including examination of blood donors. Au antigen tests should also be performed on all prospective organ donors. Recently, a cadaveric donor, who had been pronounced dead in one of our hospitals on the basis of irreversible neurologic injury, was discovered to have high titer Au antigenemia. If this had not been detected either 3 or 4 of his organs would have been transplanted and in addition his corneas would have been placed in the eye bank.
Although control of the serum hepatitis problem is predictably going to be one of the major tasks of any large transplantation program, there is no assurance that 4 such efforts will influence the high incidence of liver disease in these patients since so many recipients with negative Au tests develop abnormal hepatic function.
Other viruses, such as those responsible for infectious hepatitis (IH), could be responsible. If this were so, it would have been expected that the anticomplementary activity (ACA) might have been elevated in consequence of the formation of complexes of the virus antigen and antibody. Increases of ACA were observed by Chang and O'Brien during the IH epidemic of the Holy Cross football team. 1S However, in our patients, ACA increases were confined essentially to those renal patients with the Au antigen or to all hepatic recipients with or without Australia antigenemia. This constituted indirect evidence that infectious hepatitis was not a major factor in the liver injury found in our patients. It is conceivable that further studies of ACA will lead to a better understanding either of serum hepatitis or of the complex immunologic events in the transplant patient. The ACA examined in the present study was shown to be separate from several other recognized complement inhibitors. It was demonstrated to be distinct from C1 esterase inhibitor 21 by virtue of its heat stability, to have different physical characteristics (Fig. 7) than C3 inactivator,74, 76 and to have no relationship to rheumatoid factor.
In renal patients, the association of ACA with the Australia antigen could be made with nearly perfect reliability. If, as seems likely, the ACA in these patients consists of Au-antigen-anti-Au antibody complexes, these circulating complexes could contribute to the glomerulonephritis commonly found in the transplants 44, 69 by a mechanism comparable to that described by Oldstone and Dixon in the lymphocyte choriomeningitis virus experimental mode1. 52 In contrast, all the recipients of liver homo grafts possessed ACA, whether or not Au antigen was diagnosed. The purified ACA of one Au positive patient was shown to contain virus-like particles and surrounding halos that looked like antigenantibody complexes. However, the purified ACA of another patient who was Au negative did not have detectable virus ultrastructurally despite even higher titers. Consequently, the ACA in liver patients may have a special significance over and above any association with the Au antigen. This would not be suprising in liver recipients, inasmuch as high ACA titers have been seen in several diseases that have in common abnormalities of protein metabolism, including hypergammaglobulinemia, cryoglobulinemia, and multiple myelomaY' 19 In the absence of any evidence of an infectious etiology for progressive hepatic disease in the post-transplantation period of a given patient, serious consideration must be given to the possibility of drug hepatotoxicity with particular reference to azathioprine. G7 ,70 In such cases, a change in therapy should be considered. As a replacement for azathioprine, cyclophosphamide has received inadequate attention despite its impressive advantages. It has little hepatotoxicity,4S is one of the best immunosuppressive agents in rodents, 6,15. 23, 25, 32, 42, 73 and was even shown on a limited trial basis a number of years ago to be capable of prcvcnting renal homograft rejection in humans.23, 27, 54, 55 In one of our patients, a change was made from azathioprine to cyclophosphamide in December, 1970 . After many weeks the seriously deranged liver function tests began to improve. No deterioration in renal function has occurred during the 3 months of cyclophosphamide therapy.
Summary
The hepatitis associated or Australia (Au) antigen has been found with precipitating detection methods in the sera of almost one-fifth of a group of 89 chronic survivors after renal, hepatic, or cardiac transplantation. An additional two recipi-ents were shown to possess anti-Au antibody. Using a more sensitive complement fixation test, sevcral additional diagnoses of Au alltigenemia were made, so that 2870 of the studied patients had serologic evidence of having had or, more commonly, of having contact with the serum hepatitis virus.
Once Au antigenemia developed in the immunosuppressed patient, it seldom disappeared and these organ recipients became infectious carriers. Before detection methods for the Au antigen were available, a number of Au positive patients were unknowingly entered into the transplantation program already infected from dialysis or blood transfusion. In turn, staff members treating these carriers frequently developed aeute hepatitis and in one instance the consequencc was the death of a research technician.
In the recipients of renal homo grafts who had serial hepatic function as well as serologic tests, there was an incidence of liver malfunction at some time in the posttransplantation period exceeding 507'0.
However, the frequency of either minor or major derangements in hepatic fUllction was essentiallv the same with or without Au antigcllemia, suggesting that serum hepatitis was not an overriding or even the most important factor in the production of the well-documented liver disease that ocCllrs after renal transplantation.
Anticomplementary activity (ACA) has been said to rcflect thc presence of circulating antigcn-antibody complexes. In both the symptomatic and asymptomatic renal recipients with chronic Au antigenemia, the ACA titers were essentially always elevated. Their sera contained virus-like particles. In contrast, ACA titers were almost ne"er almormal in the Au negative renal recip:ents. This finding was construed as evidence against the pOSSibility that liver disease in the A.u negative patients was being caused by a different kind of virus, such as the infectious hepatitis (IH) variety. In some instances, drug hepatotoxicity may have been responsible. In one case, azathioprine was so strongly suspected that it was discontinued and replaced altogether with cyclophosphamidc. This kind of change in therapy should probably be considered more frequently in such cases.
In liver recipicnts, the increases in ACA were not confined to patients with Au antigenemia but were always present. In two recipients with high ACA titers, one Au negative and one Au positive, the ACA was highly purified with chromatographic techniques. The product from the Au positive serum contained virus-likc particles, whereas the ACA in the other case did not have this finding.
On the basis of much of the foregOing information about serum hepatitis under conditions of chronic immunosuppression, a patient dyillg of chronic aggressive hepatitis, Au positive, was submitted to liver replacement and then treated with azathioprine, prednisone, and heterologous ALG. vVithin minutes after host hepatcctomy, the Au antigen disappeared from the serum suggesting that the native liver had been its primary source. The antigen returned many weeks later jllst before the onset of a modcrately severe bout of hepatitis affecting the homograft. The patient has almost completely recovered from this incident and is now 8 months post-transplantation.
was before this time, so we did not dccrease our activities.
I simply bring this out to corroborate what Tom said; and that is that the ones not at risk arc the dialysis patients and the transplant patientsthe dialysis patients perhaps because they are immunosuppressed from their uremia, and the transplant patients, perhaps because they were immunosuppressed as well. All of us nonimmunosllppressed patients fit in this category (active hepatitis).
I would like to ask Tom two questions. The first relates to the claim (sic) that he has transplanted one patient with hepatitis. I am \\"Olldpring if the data that is accumulating now will indicate that, perhaps, we should consider the possibility of immullosllppressing a patient who contracts lwpatitis, lJad as that sounds? We bave toyed with this for some time because immunosuppressed patients do so well. Perhaps the major destruction to the liver occurs hecanse of thc host response to the virus in the ]h'er. If immnnosuppression is used, it may be a method of handling paticnts with hepatitis-specifically, the older patients in whom the mortality, as you know, goes up rather precipitously.
The second question has to do with an observation that he mayor may not have made on some of these patients. It has been recently reported in The Lancet that a group of patients that had hepatitis on dialysis showed an increase in erythropoitin. Thcse authors discovercd this cIFect by accident, as you know, v"hen they saw that the rcqnirement for transfusion in some patients was diminishing and they correlated this finding with patients who developed hepatitis on dialysis. They made the suggestion that under these circumstances the liver is not degrading erythropoitin jf this occurs and there were increased erythropoitin \evels, increased hcmoglobin, and a decreased need {or transfusion.
I wonder if this was seen in any of the patients that Dr. Starzl described with positive Australia antigen, or hepatitis. DR. J. GARROTT ALLEN (Palo Alto): This has been a fascinating presentation, and on a subject that I have been interested in for many years. One of the most difficult things to explain in transfusion hepatitis is the existence of the carrier donor. How does such an individual manage to harbor the infectious agent of hepatitis (presumably a virus) for so many years without himself developing evidence of liver disease? The carrier and his virus seem to adapt themselves very well to each other.
One cannot escape the concept of tolerance in such a state-tolerance of the carrier for the virus and tolerance of the virus for the carrier. If we understood this mechanism, the rejection problem of transplantation would also be solved.
The possibility of a carrier state and its relationship to impaired host immunity in hepatitis first occurred to me in 1947, when in the course of treatment of the first patient with hypo-or agammaglobulinemia, we discovered that this patient did not develop hepatitis despite our supplying her with gammaglobulin in pooled plasma and blood for the next 12 years. A similar observation has more recently been reported by a number of workers who have noted that posttransfnsion hepatitis acquired in patients on immunosuppressive therapy usually runs a very mild course. In the dialysis units and on transplantation services few if any of these patients have died of hepatitis, but this is not true of the staff taking care of these patients. As Dr. Najarian and others have noted, the fatalities have tended to occur among the personnel, people not on immunosuppressive agents. "Vitll a normal immnne response, they slowly produce antibodies, and eventually four to eight weeks later, there is a "confrontation" of the virus with the antibodies in the hepatic cells that leads to cellular destruction.
In this discussion, one is reminded of the significance and eloquence of von Pirquet and Schick's book, "Serum Sickness," first published in 1905, and translated from German into English by Schick in 19.51. The point of their study that is relevant to this discussion can be paraphrased as follows: No antibody formation-no disease. The same concept probably applies to many organisms that are nonpathogenic for man, simply because they do not provoke an antibody response. This, in a sense, is what we are approaching, it seems to me, in patients with posttransfusion hepatitis on immunosuppressive therapy, an antigen in man unable to produce antibodies. In many in stances there is no point in keeping these patients in the hospital for their hepatitis, though regulation of their immunosuppressive therapy requires it. These patients should be considered highly infectious to hospital personnel and visitors.
Dr. Najarian mentioned the possibility of treatment of hepatitis with immunosuppressive agents. We have wondered about this too, but usually by the time the patient has hepatitis, his disease is far enough advanced that immunosuppressive therapy may carry a much greater hazard than when the disease develops in a patient already on immunosuppressive therapy. As far as I know, we have had no deaths from hepatitis among patients on immunosuppressive therapy.
I would like to raise a point with Dr. Starzl: The best results for the detection of the Au antibody that I know of, are those from Dr. Prince of the New York Blood Center. As of last week, I had a letter from him to the effect that by whatever test his laboratory has attempted to use, a maximum of only twenty-five per cent of infectious donors was detected. Similar reports have come from the NIH and others. It makes one begin to question if three fourth of the cases are not due to some other agent than the Au antigen. Although Au screening is recommended, it seems rather a futile method of reducing the incidence of the disease at this time.
And this is a serious consideration, it seems to me, when one realizes that the average patient, leaving out the heart cases, gets about four units of exposure. To take one of those four possibilities ont, I don't believe is going to do anything to our present attack rate.
DR. ALAN G. BmcH (Boston): We have had the unfortunate task of reviewing the long-term data on 37 cases of clinical hepatitis which occurred on our dialysis and transplant unit during a 16 month span in 1969 and 1970. There were 14 cases occurring in dialysis patients, out of a pool of approximately 150 patients at risk, 13 cases among the 70 transplanted patients during this time, and ten cases out of about 80 staff exposed.
Our experience substantiates the impression and points made by both Dr. Starzl and Dr. Najarian and others, that there certainly is a gradation in the clinical severity in these cases. The dialysis and transplant patients have mild cases. They do, however, usually show significant enzyme rises, whereas the cases in the staff have been far more severe clinically, and one dialysis nurse and one patient's wife have succumbed from hepatic failure.
Our experience does not substantiate the contention made by Dr. Starzl that persistent Australian antigencmia is inevitable in the immunosuppressed patient. It has been our policy to decrease or discontinue Imuran when hepatitis is clinically diagnosed, and we have discontinued Imuran for 20 to 380 days, for an average of 160 days, in 12 such patients.
The Australian antigen, measured by the somewhat crude immunodiffusion technic, has remained negative in five of these patients, including one who had a positive antibody titer. Three of four patients who started with a positive Australian antigen when Imuran was discontinued, have converted to negative during the subsequent 3 to 6 months. Two patients in whom Imuran was not
